Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Eidos is a BridgeBio Pharma subsidiary focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR.